RxDoctor Payments Data

Matthew Bruha, MD

Urology · Plant City, FLNPI 1750887907

Payments from drug & device makers

$1,218in general payments, 2019–2025

Across 45 payments — averaging $27.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$399
  • Urogen Pharma, Inc.$187
  • Astellas Pharma US Inc$130
  • Endo USA, Inc.$93
  • Axonics, Inc.$83
  • Sumitomo Pharma America, Inc.$83
  • plus $243 from 6 others

What the payments were for

  • Food & beverage$1,11892%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,218 in reported general payments places this provider in the 25th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$110,470
Medicare patients
219
Services billed
1,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate31$179,444
GemtesaVibegron28$23,783
MyrbetriqMirabegron34$23,322
Solifenacin Succinate35$2,128
Estradiol30$1,600
Tamsulosin Hcl111$1,578
Oxybutynin Chloride ErOxybutynin Chloride54$1,135
Trospium Chloride30$1,120
Tolterodine Tartrate ErTolterodine Tartrate11$1,110
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst57$842
Finasteride81$836
Alfuzosin Hcl ErAlfuzosin Hcl37$708
Testosterone Cypionate11$631
Cefdinir20$127
CeftriaxoneCeftriaxone Sodium17$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$83$23,78328 claims
Astellas Pharma US IncMyrbetriq$130$23,32234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 935 urology providers in Florida.

Other urology in Plant City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →